Skip to main content

Movers & Shakers: Dec 11, 2008

Premium
Chromatography firm Dionex last week said its president and CEO Lukas Braunschweiler has resigned, effective May 31, 2009, to become CEO of Ruag Holding, a Swiss-based aviation, defense, and technology company.
 
The company will start a search soon for a replacement, it said in a statement.
 
Braunschweiler joined Dionex in the summer of 2002 replacing Blaine Bowman as president and CEO. Before than he was group vice president and head of the laboratory and packaging divisions at Mettler-Toledo.
 

 
Tyrian Diagnostics, formerly called Proteome Systems, last week announced the appointment of Merilyn Sleigh to and the resignation of John Martin from the company’s board.
 
Sleigh is a member of the Australian government’s task force developing a 10-year strategy for the country’s pharmaceutical industry. She also advises the Australian Commonwealth Scientific and Industrial Research Organisation and the Garvan Institute for Medical Research on commercialization efforts.
 
She is a non-executive director of nutritional firm Clover; drug-discovery company Mimetica; and the Rural Industries Research and Development Council.
 
Martin had been a director of the company since 2000, and a non-executive director since 2004 when he left the company as deputy CEO. He is currently managing director of Babcock & Brown, a developer and operator of senior living communities.
 

 
Strategic Diagnostics announced this week that CFO Stanley Fronczkowski will step down on April 3, 2009, to pursue other interests.
 
Fronczkowsik was appointed CFO of SD in January 2007 after 29 years at Keystone Foods in various management positions. SD has initiated a national search for his replacement and engaged head-hunting firm Spencer Stuart to assist in the process.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.